-

Sage Therapeutics to Present at Upcoming May Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following upcoming investor conferences in May:

  • Bank of America Health Care Conference: fireside chat on Tuesday, May 11, 2021 at 10:15 am ET.
  • RBC Capital Markets Global Healthcare Conference: fireside chat on Tuesday, May 18, 2021 at 8:35 am ET.

A live webcast of each presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Contacts

Investor
Jeff Boyle, 617-949-4256
Jeff.Boyle@sagerx.com

Media
Maureen L. Suda, 617-949-4289
maureen.suda@sagerx.com

Sage Therapeutics, Inc.

NASDAQ:SAGE

Release Versions

Contacts

Investor
Jeff Boyle, 617-949-4256
Jeff.Boyle@sagerx.com

Media
Maureen L. Suda, 617-949-4289
maureen.suda@sagerx.com

More News From Sage Therapeutics, Inc.

Sage Therapeutics Announces Second Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with...

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi...

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeu...
Back to Newsroom